 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| KEGG |
|
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C18H23NO2 |
| Molar mass | 285.387 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Ketazocine (INN), also known asketocyclazocine, is abenzomorphan derivative used inopioid receptor research. Ketazocine, for which the receptor is named, is anexogenous opioid that binds to theκ opioid receptor.[1]
Activation of this receptor is known to cause sleepiness, a decrease in pain sensation and (potentially)dysphoria,paranoia, andhallucinations. It also causes an increase in urine production because it inhibits the release ofvasopressin.
Unlike other opioids, substances that only bind to the κ receptor theoretically do not depress therespiratory system.
The crystal structure of ketazocine was determined in 1983.[2]
